(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2011 (30.06.2011)

PCT

(10) International Publication Number
WO 2011/079257 A3

(51) **International Patent Classification**:
C07K 16/22 (2006.01)

(21) **International Application Number**:
PCT/US2010/061987

(22) **International Filing Date**:
23 December 2010 (23.12.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/290,092	24 December 2009 (24.12.2009)	US
61/306,359	19 February 2010 (19.02.2010)	US
61/328,316	27 April 2010 (27.04.2010)	US
61/349,273	28 May 2010 (28.05.2010)	US
61/356,126	18 June 2010 (18.06.2010)	US

(71) **Applicant** *(for all designated States except US)*: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **SLEEMAN, W., Mark** [US/US]; 118 Lake Drive, Mahopac, NY 10541 (US). **GUSAROVA, Viktoria** [US/US]; 3315 Park Place, Springfield, NJ 07081 (US). **KIM, Jee, H.** [US/US]; 25 Bank Street, #222k, White Plains, NY 10606 (US). **CHEN, Gang** [US/US]; 2478 Mill Pond Road, Yorktown Heights, NY 10598 (US).

(74) **Agent**: **IZUMI, Yokoyama**; Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
18 August 2011

WO 2011/079257 A3

(54) **Title**: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4

(57) **Abstract**: A fully human antibody or antigen -binding fragment of a human antibody that specifically binds and inhibits human angiopoietin - like protein 4 (hANGPTL4) is provided. The human anti- hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti -hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity.